Insmed Incorporated
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- William H. Lewis
- Full Time Employees
- 1,664
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 700 US Highway 202/206 Bridgewater NJ United States 08807
- IPO Date
- Feb 15, 1991
- CIK
- 0001104506
- Website
- insmed.com
- Similar Companies
- Business
- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company founded in 1988 and headquartered in Bridgewater, New Jersey, focuses on rare diseases with investigational and approved therapies in pulmonary, inflammatory, and other serious conditions; its approved products include ARIKAYCE (amikacin liposome inhalation suspension) for Mycobacterium avium complex lung disease in adults with limited treatment options and BRINSUPRI (brensocatib), a first-in-class neutrophil elastase inhibitor for non-cystic fibrosis bronchiectasis; the company advances a pipeline encompassing TPIP for pulmonary arterial hypertension, INS1201, and preclinical programs in gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue, serving patients primarily through clinical trials and commercial launches targeting chronic lung diseases. Insmed operates 9 corporate offices and 4 global research sites across the United States, Europe, Japan, and other regions, with over 1,500 employees as of mid-2025. Recent developments include FDA approval of BRINSUPRI in 2025 and its subsequent European Union approval, topline results from the Phase 2b pulmonary arterial hypertension study and Phase 3 ASPEN study in 2024-2025, the opening of a new research lab in Cambridge, UK, a proposed $650 million public offering of common stock in June 2025, raised full-year 2025 ARIKAYCE revenue guidance to $420-430 million, and repeated recognition as the No. 1 biopharma employer by Science magazine.
Company News
Insmed: A Blockbuster Launch, Priced Ahead Of Its Own Guidance
Buy, Sell, or Hold? Wednesday’s Top Upgrades and Downgrades: Adobe, Apple, Duolingo, Exxon Mobil, Fiserv, Fortinet, Gartner, Lockheed Martin, Skyworks Solutions, Visa and More
Insmed to Present at November and December 2026 Investor Conferences
Insmed Incorporated (INSM) Q3 2026 Earnings Call Transcript
INSM Q3 Earnings Miss, Stock Soars on Sales Beat & Raised Guidance
What Insmed (INSM) Said on Its Q3 Earnings Call
Insmed (INSM) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Insmed (INSM) Reports Q3 Loss, Tops Revenue Estimates
Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update
Citizens Financial Group Inc. RI Makes New Investment in Insmed, Inc. $INSM
Insmed (INSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Insmed Appoints Two New Directors to Its Board
Insmed Launches BRINSUPRI® Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan
Insmed Features the Global Phase 3 PALM Clinical Development Program Evaluating Treprostinil Palmitil Inhalation Powder (TPIP) at CHEST 2026
Insmed to Present New Data Across Its Respiratory Portfolio at CHEST 2026 and IDWeek 2026
Perpetual Ltd Acquires 5,760 Shares of Insmed, Inc. $INSM
This Insmed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
INSM Stock Slides on CFO Exit, Reiterates '26 Sales View
Insmed Stock Slides — CFO Exit Date Set, 2026 Guidance Reaffirmed
Insmed Announces CFO Transition